For the first time in the modern history of federal cannabis enforcement, state-licensed medical marijuana businesses are positioned to claim ordinary business deductions on their federal tax returns. The change follows a final order issued jointly by the Department of Justice and the Drug Enforcement Administration formally transferring FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act - and on April 23, 2026, the Treasury Department and IRS confirmed what that shift means, in tax terms, for the industry: the foundational trigger for I.R.C. § 280E no longer applies to qualifying operations.
What Section 280E Actually Did - and Why It Hurt So Much
To understand the magnitude of this shift, it helps to remember what § 280E has meant in practice. The provision, enacted in 1982 after a court allowed a drug dealer to deduct his business expenses, prohibits any deduction or credit for a trade or business that consists of "trafficking in controlled substances" listed under Schedule I or II of the CSA. For state-licensed cannabis companies, that meant paying federal income tax on gross profit rather than net income. Rent, payroll, marketing, professional services - none of it deductible. Only the cost of goods sold, calculated under I.R.C. § 471, offered any relief.
The financial toll was severe. Cannabis businesses routinely faced effective federal tax rates far exceeding those borne by any comparable legal industry, sometimes well above 50 percent of gross revenue. Multi-state operators carrying significant overhead built entire accounting departments around § 280E compliance and mitigation - a costly exercise in damage control, not tax planning.
Now, for operations that qualify under the rescheduled category, that statutory trap is gone. The IRS confirmed in its April 23 release that rescheduling "generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances under the CSA."
The Transition Rule: Generous, Prospective, and Precisely Limited
Here's where the practical planning gets interesting. Rather than requiring tax practitioners to bisect the fiscal year at the exact moment the Final Order took effect - April 22, 2026 - the Treasury has signaled a full-year transition rule. Under that approach, qualifying medical marijuana businesses may treat the entirety of the taxable year containing the effective date as free from § 280E's reach, not merely the portion following April 22.
That is a taxpayer-favorable reading. It sidesteps what would otherwise be an accounting nightmare: mid-year cost segregation, bifurcated payroll analyses, and apportioned rent schedules built around a single calendar date. For calendar-year filers, the 2026 return is, in effect, a clean break.
What Treasury's release does not do is extend that generosity backward. The DEA, in the text of the Final Order itself, explicitly encouraged the Secretary of the Treasury to consider "providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license." The IRS response to that recommendation, as of late April 2026, is silence. No amended return pathway. No refund mechanism. No indication that prior-year liabilities are under review.
That silence is not surprising - it is consistent with how the IRS interprets retroactive statutory relief - but it will sting for operators who paid, in some cases, years of inflated tax bills while running businesses that were simultaneously licensed and regulated by state governments. The DEA acknowledged its own jurisdictional boundary plainly: "Nothing in this rule constitutes a determination regarding federal tax liability." Fair enough. But the gap between what the DEA encouraged and what Treasury has actually committed to remains wide.
Mixed Operations: Where the Real Complexity Begins
The rescheduling order is not a blanket amnesty for the cannabis industry. The DEA explicitly left unlicensed marijuana crops, bulk marijuana, and products not yet incorporated into an FDA-approved formulation in Schedule I. That distinction creates a genuinely complicated situation for businesses operating across both medical and adult-use markets - which describes a substantial portion of multi-state operators.
A single company might simultaneously hold a state medical license for dispensary sales and distribute recreational products that remain firmly in Schedule I territory. Under the incoming guidance, § 280E still applies - in full - to the Schedule I activities. Treasury has confirmed that forthcoming regulations will "clarify the ways in which, for businesses with multiple activities, section 280E applies only to those activities related to trafficking in Schedule I or II controlled substances," with expense apportionment as the operative mechanism.
That phrase - expense apportionment - is doing a lot of heavy lifting. What it means in practice is that tax practitioners will need to build defensible cost-accounting frameworks that allocate overhead, rent, and payroll between revenue streams tied to Schedule I activity and those tied to Schedule III. The traditional COGS-centered approach under § 471, which was the primary mitigation tool under old § 280E, will no longer be sufficient on its own. Expect detailed IRS regulations specifying permissible allocation methodologies, with scrutiny on how shared resources - a single grow facility, a shared distribution network, common administrative staff - get carved up.
The practical implication for CPAs and enrolled agents advising mixed-license clients: begin building those apportionment methodologies now, before the formal guidance drops in the Internal Revenue Bulletin. Waiting until the regulations are final and then reconstructing prior-period allocations is not a strategy; it is an audit risk.
What Comes Next, and What Practitioners Should Watch
The April 23 Treasury release is a press release, not binding guidance. The regulations that will actually govern tax treatment - including the transition rule and the apportionment standards - will be published in the Internal Revenue Bulletin, and that publication has not yet occurred as of the Treasury's announcement. Until it does, the specific parameters of relief remain preliminary.
One question the guidance will need to resolve is how "qualifying" medical operations are defined for purposes of the full-year transition rule. The Final Order's criteria center on state licensure and FDA-approval status, but the intersection of those standards with the IRS's own definitions is not yet settled. Another open question involves state conformity: many states with their own cannabis tax regimes have historically piggybacked on federal treatment, and several will need to update their own codes to reflect the federal rescheduling - or explicitly decouple from it.
The retrospective relief question, however, is the one most practitioners should resist rushing toward. Amending prior-year returns to claim deductions that were legally prohibited under § 280E at the time of filing - before Treasury has sanctioned that approach - is an aggressive position with meaningful audit exposure. The DEA's encouragement was exactly that: an encouragement, not a legal determination. Unless and until Treasury explicitly opens a retroactive relief pathway, amended returns on that basis carry real risk.
The rescheduling of medical marijuana is a genuine inflection point for an industry that has operated under punishing federal tax conditions for decades. The relief is substantial and, for calendar-year medical operators in 2026, immediate. But the architecture of that relief - what qualifies, how expenses get split, and whether the past can be revisited at all - is still being built.
